Enzymatica AB: Extraordinary shareholders' meeting on changes to the board of directors

Press release
Lund, 1 December 2016

Enzymatica: Extraordinary shareholders' meeting on changes to the board of directors

The board of directors of Enzymatica has resolved to convene an extraordinary shareholders' meeting to be held on 19 December 2016 regarding changes to the composition of the board of directors. Bengt Baron is proposed as new chairman of Enzymatica and Mats K Andersson and Louise Nicolin as new board members. A notice convening the extraordinary shareholders' meeting is to be distributed within short. The company has been informed that shareholders representing more than 50 per cent of the shares and votes of Enzymatica support the proposal.

The background of the resolution by the board of directors to convene an extraordinary shareholders' meeting is that the new large shareholders of Enzymatica wish to have influence on the company's operations and that the board of directors represents the new shareholder structure in a more appropriate manner. The company has been informed that Gudmundur Palmason and Sigurgeir Gudlaugsson with families (directly and indirectly through companies), Mats K Andersson (directly and indirectly through companies), Fibonacci Asset Management AB and RoosGruppen AB are supporting the proposal. These investors became shareholders earlier this year in connection with Enzymatica's acquisition of the Icelandic company Zymetech and through the implementation of two new share issues, which provided Enzymatica with a capital contribution of approximately MSEK 100 before issue expenses. At the same time, it has been Lennart Nilsson's (Enzymatica's present chairman) wish, after the acquisition of Zymetech and the new share issues, to hand over the chairmanship to somebody who can follow the company during a longer period.

The proposal entails that the company's board of directors will consist of six ordinary board members compared to today's seven board members, that the board members Lennart Nilsson, Hans Pihl, Nils Siegbahn and Monica Wallter will leave the board of directors and that Bengt Baron, Mats K Andersson and Louise Nicolin will be appointed as new board members up to and including the next annual general meeting. Marianne Dicander Alexandersson, Gudmundur Palmason and Sigurgeir Gudlaugsson remain as board members. Bengt Baron is proposed chairman of the board of directors.

Bengt Baron
Born 1962. BSc in Business Administration and MBA from University of California, Berkeley. Bengt currently has appointments as chairman of the board in MIPS AB and as board member in Thule Group AB (publ) and 5653 Sweden AB. Bengt has previously been CEO of Cloetta AB and Leaf International B.V. Holdings: No shares in the company.

Mats K Andersson
Born 1955. Education in International Economics from Lund University. Mats currently has appointments as chairman of the board in Lomond Invest AB, Abanico Invest AB and Andersson & Co AB, and as board member in Volati Parts AB and Hills Golf AB. Mats has previously been CEO at Lomond Industrier AB and Business Unit Manager and deputy CEO at LICare AB (publ). Holdings: 11,346,951 shares in the company (directly and indirectly through companies).

Louise Nicolin
Born 1973. MSc in Molecular Biotechnology from Uppsala University. Exc. MBA from Stockholm School of Business. Louise currently has appointments as chairman of the board in Better Business World Wide and as board member in Volati AB (publ), VBG Group AB (publ), Uppdragshuset Sverige AB and board assignments within Dellner Couplers AB. Louise is since year 2000 running a consultant business in Nicolin Consulting AB with focus on business development and quality assurance, and has previously been Business Unit Manager and Consultant Manager at PlantVision AB.
Holdings: No shares in the company.

For more information, please contact:

Lennart Nilsson, Styrelseordförande Enzymatica AB
Tel: +46 705-12 32 95 | E-post: lennart.nilsson@crafoord.se

This information is information that Enzymatica AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 AM CET on 1 December 2016.

About Enzymatica AB
Enzymatica is a life science company who develops and sells medical device products against infectious-related diseases. Over a short period the company has developed a unique oral spray for colds, ColdZyme®, and launched it on six markets. The product has become one of the leading articles for colds in Swedish pharmacies. Enzymatica's strategy is to continue growing by strengthening its position in existing markets and to expand to more geographical markets through well-established partners. The company is headquartered in Lund, Sweden and is listed on Nasdaq First North. For more information, please visit www.enzymatica.com.

Enzymatica's Certified Adviser is Erik Penser Bankaktiebolag.